Category Archives: Inside BIO Industry Analysis

Biobased Companies Take A Closer Look At Sustainability

BIO Logo Horizontal 4C copy

BIO and its member companies are constantly working together to help shift the world’s reliance on petroleum-based products to a reliance on biobased and greener products. In a recent piece by Chemical & Engineering News, Melody Bomgardner highlights BIO’s work with it’s member companies to create a more sustainable supply chain in effort create environmentally friendlier products for consumers. Here are some notable points from her piece: “Thanks to the emerging bioeconomy, renewable substances made from plants Read More >

Biofuels & Climate Change  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Will We Ever Have Genetically Modified Meat?

LBS-graphic-200x100 copy

Currently, there are no genetically engineered animals sold for human consumption on the market, reports Popular Science. As you might have guessed, the lack of genetically modified meat on the market isn’t because of a lack of technology or safety; it’s because of the politics. GM foods are deeply unpopular as of now, and GM food animals are especially so. After reading an article concerning GM animals from The Scientist showing how effective they can be, Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Bioeconomics: Everybody’s Doing It

medical_research

It is everywhere. In March, the US State Department held a one-day conference titled “Showcasing the Bioeconomy: The Future is Now”. That same month, the UK House of Lords published a report on the same topic. “Waste could be turned into wealth,” they said. In the past couple of weeks, Finland’s first national bioeconomy strategy was unveiled, while the Borneo Post reported that “The vast potentiality of bioeconomy has been regarded as one of the Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Therapeutic Licensing and M&A Deals

lab_tech

Licensing deals for therapeutic candidates in 2013 dropped to the lowest volume in at least eight years for deals with disclosed values totaling over $10M. Total upfront payments to biotechs were also at an eight year low, with only $1.9B paid to biotechs in 2013. This is a 50 percent drop from peak levels. However, there is a silver lining in the data: Preclinical deal volume saw a slight increase in 2013, and has not Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

Debunking the Biotech Bubble Talk

Chart

The Nasdaq Biotechnology Index (NBI) has been on a wild ride in 2014 with a 20 percent gain in the first two months, a 24 percent drop from late February to mid-April, and a rebound of 16 percent off April lows by early June. This recent sell-off follows a 130 percent gain over the last three years and the debut of 100 biotech IPOs, leading some investors to ask if the recent sell-off is the Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,